A superior, next generation
transgenic platform

Tailored licensing options

Ablexis Announces Licensing Agreement
with Memorial Sloan Kettering Cancer Center

About

The industry's leading transgenic platform.

MORE
Technology

For efficient discovery and development of antibody and antibody-derivative drug candidates.

MORE
Licensing

Our license options are designed to meet the needs of our partners.

MORE
News

Ablexis Announces Licensing Agreement with Memorial Sloan Kettering Cancer Center

MORE